invivodata inc.announced it has expanded its portfolio of global ePRO services by providing Asian language help desk support. Operated by invivodata’s service partner C3i Inc., in Dalian, China, invivodata’s help desk now provides comprehensive technical support in Chinese, Korean, or Japanese. The Asian language help desk has been available since August 2011.
invivodata’s Asian language support service is an extension of it’s established strategic partnership with C3i, a leading IT services provider serving the life sciences industry. Through this partnership, invivodata delivers a scalable support solution with many benefits, including prompt and accurate resolution of inquiries, professionally-trained support staff with diverse language capabilities, real-time access to a detailed knowledge base, and sophisticated systems to log all calls.
“We are pleased to offer Asian language support as a key service to biopharmaceutical and medical device researchers who are using invivodata’s ePRO systems in their clinical trials throughout Asia,” said Wolfgang Summa PhD, Vice President of Worldwide Operations at invivodata. “Through our experience in running over 350 global clinical trials to date, we have identified that a robust, native-language help desk is critical to ensuring smooth and successful ePRO implementation. This is especially true with Asian sites. By leveraging the existing support framework we have with C3i, we are able to seamlessly extend this valuable service, which enables us to meet the evolving needs of our new and existing customers as they expand into the Asian markets."
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.